Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.
The institutes have led over 1,000 studies, published 5,500 manuscripts in the peer review literature (including 144 in the New England Journal) and have led 60 FDA submissions from their network of 7,000 sites worldwide. In 2014 and 2018 - 2020 Gibson was ranked as one of the world's most highly cited authors in all of science in the past decade by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 136,000 times, and he has an H index of 129 and an i10-index of 523.
Disclosure information not submitted.
LATE-BREAKING CLINICAL TRIALS | SATURDAY
Saturday, March 7, 2026
2:30 PM - 3:45 PM EST
In Home Therapy for ST Elevation MI
Sunday, March 8, 2026
3:34 PM - 3:42 PM EST
Panel Discussion | Thrombus Management and Anticoagulation
Sunday, March 8, 2026
4:06 PM - 4:26 PM EST
Sunday, March 8, 2026
4:42 PM - 4:50 PM EST
Panel Discussion | ACS & AMI 2025 Contemporary Topics
Sunday, March 8, 2026
5:22 PM - 5:45 PM EST
Cutting out bricks & mortar in clinical trials: Direct to Participant virtual trials is the future
Monday, March 9, 2026
9:10 AM - 9:18 AM EST
Panel Discussion |Are AI-based Technologies evolving Cardiovascular Patient Engagement?
Monday, March 9, 2026
9:42 AM - 10:00 AM EST
Minimizing the Inferiority of Non-Inferiority Trials
Monday, March 9, 2026
8:37 AM - 8:45 AM EST
BEYOND THE GUIDELINES | DE-ESCALATION OF ANTIPLATELET THERAPY
Monday, March 9, 2026
4:00 PM - 5:15 PM EST
When can you Drop Triple Therapy After PCI?
Monday, March 9, 2026
4:32 PM - 4:40 PM EST
Panel Discussion | From EFS to Real World Data
Tuesday, March 10, 2026
11:44 AM - 12:10 PM EST